Integer Holdings Corporation (ITGR) SEC Filings & Earnings Calls

Regulatory approval still required; transaction may not close if conditions not satisfied.

“Transaction is subject to the satisfaction or waiver of customary closing conditions, including receipt of required regulatory approvals.”

Merger litigation risk: lawsuits seek to enjoin merger; supplemental disclosures issued but no assurance of outcome.

“Three complaints filed; demand letters; company denies merit but supplements proxy.”

Potential dilution if holders convert and company elects stock settlement for excess over principal.

“The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Notes being converted.” · word for word

Deal subject to shareholder approval, regulatory clearances, and no material adverse effect; financing committed but execution risk remains.

“Closing conditions include stockholder approval, HSR clearance, no Company Material Adverse Effect.”

Merger Completion Risk

“The pending Merger may be delayed or not occur at all for a variety of reasons, including that the Merger is terminated, and the failure to complete the Transaction could adversely affect our business, results of operations, financial condition, and the market price of our common stock.” · word for word

New Product Adoption Risk

“In 2026, we expect year over year sales growth to be primarily impacted by lower sales related to three new products due to lower than anticipated market adoption.” · word for word

Transaction may not close due to regulatory or shareholder approval

“Subject to stockholder approval, regulatory approvals, and other conditions”

Pending acquisition introduces deal completion risk and regulatory approvals

“Integer and KKR announced they have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire all of the outstanding shares of Integer” · word for word

Sales decline in Cardio & Vascular and Other Markets segments

“Cardio & Vascular sales decreased 2% to $280 million; Other Markets sales totaled $10 million, compared to $18 million in prior year”

Guidance withdrawn due to pending transaction, creating uncertainty for near-term outlook

“Given the pending transaction, Integer is withdrawing its previously issued financial outlook” · word for word

New product headwinds pressuring sales and margins

“headwinds associated with the three new products” · word for word

Elevated leverage ratio at 3.2x

“leverage ratio of 3.2 times adjusted EBITDA” · word for word

Demand Risk for New Products

“In 2026, we expect year over year sales growth to be primarily impacted by lower sales related to three new products due to lower than anticipated market adoption.” · word for word

Strategic Review Uncertainty

“In April 2026, we announced that the Board had initiated a strategic review to maximize stockholder value.” · word for word

Securities Class Action Lawsuit

“On December 10, 2025, a putative class action lawsuit was filed in the United States District Court for the Southern District of New York against Integer and certain of its executives” · word for word

Gross Margin Pressure

“Gross margin declined in the first quarter of 2026, compared to the same prior year period due to the negative impact of lower fixed cost absorption” · word for word

Liquidity Risk

“Cash and cash equivalents decreased to $8.1M from $17.1M at year-end 2025.”

Tariff impact on profitability

“the Committee adjusted the STI AOI performance target downward by $15 million, with the understanding that if the impact of tariffs impacted AOI by less than $15 million, the 2025 STI payout factor would be reduced.” · word for word

Key person dependence / CEO transition

“Mr. Khales was appointed President and CEO, effective as of October 24, 2025, in connection with the planned CEO transition and retirement of Joseph Dziedzic.” · word for word

Activist involvement may lead to strategic or operational changes; standstill reduces near-term disruption.

“Cooperation agreement with standstill and voting commitments; board refresh.”

Customer Concentration

“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.” · word for word

Raw Material Price Volatility

“Many of the raw materials that are used in our products are subject to fluctuations in market price. In particular, the prices of precious metals, such as gold or platinum, have historically fluctuated.” · word for word

Supply Chain Concentration

“We purchase some critical raw materials from a limited number of suppliers due to the technically challenging requirements of the supplied product.” · word for word

Leverage ratio of 3.0x adjusted EBITDA due to acquisitions and share repurchases

“Total debt increased $195 million to $1.185 billion. Non-GAAP net total debt increased $236 million to $1.190 billion, primarily to finance acquisitions, costs associated with the 2030 convertible notes offering, and share repurchases, resulting in a leverage ratio of 3.0 times adjusted EBITDA” · word for word

Leadership transition risk is low as it was planned and new CEO is internal.

“Planned transition, new CEO previously COO and led Cardio & Vascular business.”

Customer concentration and demand risk

“We recently updated our sales outlook for 2025, primarily to reflect lower than anticipated demand for select emerging customers’ products.” · word for word

New product adoption risk

“The market adoption of these products has been lower than anticipated.” · word for word

Convertible note dilution risk

“The conversion of our 2028 Convertible Notes, diluting ownership interests of existing holders of our common stock.” · word for word